365 related articles for article (PubMed ID: 26980506)
1. A surveillance system of Invasive Pneumococcal Disease in North-Eastern Italy.
Baldovin T; Lazzari R; Russo F; Bertoncello C; Buja A; Furlan P; Cocchio S; Palù G; Baldo V
Ann Ig; 2016; 28(1):15-24. PubMed ID: 26980506
[TBL] [Abstract][Full Text] [Related]
2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
3. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
4. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
5. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
6. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
7. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
8. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW;
J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477
[TBL] [Abstract][Full Text] [Related]
9. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
10. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
[TBL] [Abstract][Full Text] [Related]
11. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
12. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
[TBL] [Abstract][Full Text] [Related]
13. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
[TBL] [Abstract][Full Text] [Related]
14. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
[TBL] [Abstract][Full Text] [Related]
15. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
16. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.
Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C;
Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302
[TBL] [Abstract][Full Text] [Related]
17. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
[TBL] [Abstract][Full Text] [Related]
18. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
20. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
